Sharon Griswold, MD, MPH, Mustfa K. Manzur, MD, MPH, MS, and Wendy Dean, MD
Practice ownership shifts to various employment models have amplified the problem of physician-employees of some US health care companies not knowing about services billed in their names.
AMA J Ethics. 2022; 24(11):E1049-1055. doi:
10.1001/amajethics.2022.1049.
More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
AMA J Ethics. 2022; 24(11):E1069-1074. doi:
10.1001/amajethics.2022.1069.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022; 24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022; 24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Dr Isa Ryan joins Ethics Talk to discuss her article, coauthored with Dr Ashish Premkumar and Professor Katie Watson: “Why the Post-Roe Era Requires Protecting Conscientious Provision as We Protect Conscientious Refusal in Health Care.”